BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 8650403)

  • 1. [LDL apheresis using a double filtration technique. Results after a 6-to-12 month follow-up in patients with refractory hyperlipemia and ischemic heart disease].
    Rubio Sanz R; Anaya F; López-Sendón JL; López de Sa E; Muñoz H; García E; Delcán JL
    Rev Esp Cardiol; 1996 Apr; 49(4):270-6. PubMed ID: 8650403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical long-term results of H.E.L.P.-apheresis].
    Schuff-Werner P
    Z Kardiol; 2003; 92(Suppl 3):III28-9. PubMed ID: 14663598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LDL apheresis: a novel technique (LIPOCOLLECT 200).
    Stefanutti C; Di Giacomo S; Mazzarella B; Castelli A
    Artif Organs; 2009 Dec; 33(12):1103-8. PubMed ID: 19995360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One year experience with a low density lipoprotein apheresis system.
    Durst R; Rund D; Schurr D; Eliav O; Ben-Yehuda D; Shpizen S; Ben-Avi L; Schaap T; Pelz I; Leitersdorf E
    Isr Med Assoc J; 2002 Sep; 4(9):677-80. PubMed ID: 12440228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of early graft occlusion after coronary bypass grafting by post-operative reduction of plasma fibrinogen by H.E.L.P. apheresis. First evaluation of 12 patients treated during our study (44 bypasses)].
    Blessing F; Jaeger BR; Oberhoffer M; Reichart B; Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III42-7. PubMed ID: 14663601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term effect of LDL apheresis on coronary heart disease.
    Donner MG; Richter WO; Schwandt P
    Eur J Med Res; 1997 Jun; 2(6):270-4. PubMed ID: 9182655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of LDL-apheresis on the long-term prognosis of hypercholesterolemic patients with coronary artery bypass grafts: a multicenter study].
    Kito Y; Takahashi J; Endo M; Agishi T; Kitamura S; Matsuda H; Fujiwara T; Dohi T; Ito T; Kawashima Y
    Kyobu Geka; 1993 May; 46(5):399-404. PubMed ID: 8492490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy].
    Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III6-27. PubMed ID: 14663597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group.
    Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T
    Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apheresis technologies for prevention and regression of atherosclerosis: clinical results.
    Bambauer R; Schneidewind JM; Latza R
    ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein apheresis: principles and indications.
    Winters JL
    Semin Dial; 2012; 25(2):145-51. PubMed ID: 22277063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient.
    Jansen M; Gabriel H; Banyai S; Pidlich J; Weidinger F; Hörl WH; Derfler K
    Wien Klin Wochenschr; 1996; 108(14):425-31. PubMed ID: 8784984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years.
    Palcoux JB; Atassi-Dumont M; Lefevre P; Hequet O; Schlienger JL; Brignon P; Roussel B
    Ther Apher Dial; 2008 Jun; 12(3):195-201. PubMed ID: 18503695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In face of the increasing efficacy of lipid-lowering therapy, is there still a place for LDL-apheresis?
    Stegmayr B; Lalau JD; Johnson O
    Transfus Apher Sci; 2004 Jun; 30(3):213-20. PubMed ID: 15172626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hyperlipidemia with a modified low density lipoprotein apheresis system with dextran sulfate.
    Zhao YH; Zou YG; Sun QJ; Xi D; Xing CY
    Ther Apher Dial; 2007 Aug; 11(4):249-54. PubMed ID: 17661829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving cholesterol target in a managed care organization (ACTION) trial.
    Straka RJ; Taheri R; Cooper SL; Smith JC
    Pharmacotherapy; 2005 Mar; 25(3):360-71. PubMed ID: 15843283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies.
    Bambauer R; Schiel R; Latza R
    Ther Apher; 2000 Jun; 4(3):213-7. PubMed ID: 10910023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of long-term lipid apheresis at a single center.
    Koziolek MJ; Hennig U; Zapf A; Bramlage C; Grupp C; Armstrong VW; Strutz F; Müller GA
    Ther Apher Dial; 2010 Apr; 14(2):143-52. PubMed ID: 20438535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of homozygotic familial hypercholesterolemia with continuous apheresis of low density lipoproteins].
    Teruel JL; Lasunción MA; Castañón MA; Gallego N; Herrera E; Ortuño J
    Med Clin (Barc); 1991 Nov; 97(19):738-40. PubMed ID: 1800863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis.
    Bosch T; Lennertz A; Schenzle D; Dräger J;
    J Clin Apher; 2002; 17(4):161-9. PubMed ID: 12494408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.